Rho kinase and hypertension

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 12, 2010, Pages 1276-1284

  Wirth, Angela ^a  

^a MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

Hypertension; NO signalling; Rho kinase; Rho kinase inhibitors; Statins

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; COMPACTIN; EZETIMIBE; FASUDIL; FLUINDOSTATIN; GSK 269962 A; H 1152 P; HYDROXYFASUDIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE DONOR; RHO KINASE; RHO KINASE INHIBITOR; SB 772077 B; SLX 2119; UNCLASSIFIED DRUG; WF 536; Y 39983;

BRAIN VASOSPASM; CAROTID ARTERY OBSTRUCTION; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; HUMAN; HYPERTENSION; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTILITY; SMOOTH MUSCLE FIBER; STRESS FIBER; STROKE;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; HYPERTENSION; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; VASCULAR RESISTANCE;

EID: 78049265296     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.05.002     Document Type: Review

References (124)

1. Etienne-Manneville S., Hall A. Rho GTPases in cell biology. Nature 2002, 420:629-635.
2. Takahashi N., Tuiki H., Saya H., Kaibuchi K. Localization of the gene coding for ROCK II/Rho kinase on human chromosome 2p24. Genomics 1999, 55:235-237.
3. Nakagawa O., Fujisawa K., Ishizaki T., Saito Y., Nakao K., Narumiya S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 1996, 392:189-193.
4. Leung T., Manser E., Tan L., Lim L. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J. Biol. Chem. 1995, 270:29051-29054.
5. Riento K., Ridley A.J. Rocks: multifunctional kinases in cell behaviour. Nat. Rev. Mol. Cell Biol. 2003, 4:446-456.
6. Leung T., Chen X.Q., Manser E., Lim L. The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol. Cell. Biol. 1996, 16:5313-5327.
7. Wibberley A., Chen Z., Hu E., Hieble J.P., Westfall T.D. Expression and functional role of Rho-kinase in rat urinary bladder smooth muscle. Br. J. Pharmacol. 2003, 138:757-766.
8. Hiroki J., Shimokawa H., Higashi M., Morikawa K., Kandabashi T., Kawamura N., Kubota T., Ichiki T., Amano M., Kaibuchi K., Takeshita A. Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J. Mol. Cell. Cardiol. 2004, 37:537-546.
9. Sin W.C., Chen X.Q., Leung T., Lim L. RhoA-binding kinase alpha translocation is facilitated by the collapse of the vimentin intermediate filament network. Mol. Cell. Biol. 1998, 18:6325-6339.
10. Katoh K., Kano Y., Amano M., Onishi H., Kaibuchi K., Fujiwara K. Rho-kinase-mediated contraction of isolated stress fibers. J. Cell Biol. 2001, 153:569-584.
11. Amano M., Chihara K., Nakamura N., Kaneko T., Matsuura Y., Kaibuchi K. The COOH terminus of Rho-kinase negatively regulates rho-kinase activity. J. Biol. Chem. 1999, 274:32418-32424.
12. Ishizaki T., Maekawa M., Fujisawa K., Okawa K., Iwamatsu A., Fujita A., Watanabe N., Saito Y., Kakizuka A., Morii N., Narumiya S. The small GTP-binding protein Rho binds to and activates a 160kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J. 1996, 15:1885-1893.
13. Feng J., Ito M., Kureishi Y., Ichikawa K., Amano M., Isaka N., Okawa K., Iwamatsu A., Kaibuchi K., Hartshorne D.J., Nakano T. Rho-associated kinase of chicken gizzard smooth muscle. J. Biol. Chem. 1999, 274:3744-3752.
14. Sebbagh M., Renvoize C., Hamelin J., Riche N., Bertoglio J., Breard J. Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat. Cell Biol. 2001, 3:346-352.
15. Sebbagh M., Hamelin J., Bertoglio J., Solary E., Breard J. Direct cleavage of ROCK II by granzyme B induces target cell membrane blebbing in a caspase-independent manner. J. Exp. Med. 2005, 201:465-471.
16. Riento K., Guasch R.M., Garg R., Jin B., Ridley A.J. RhoE binds to ROCK I and inhibits downstream signaling. Mol. Cell. Biol. 2003, 23:4219-4229.
17. Ward Y., Yap S.F., Ravichandran V., Matsumura F., Ito M., Spinelli B., Kelly K. The GTP binding proteins Gem and Rad are negative regulators of the Rho-Rho kinase pathway. J. Cell Biol. 2002, 157:291-302.
18. Kimura K., Ito M., Amano M., Chihara K., Fukata Y., Nakafuku M., Yamamori B., Feng J., Nakano T., Okawa K., Iwamatsu A., Kaibuchi K. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 1996, 273:245-248.
19. Shimizu H., Ito M., Miyahara M., Ichikawa K., Okubo S., Konishi T., Naka M., Tanaka T., Hirano K., Hartshorne D.J., et al. Characterization of the myosin-binding subunit of smooth muscle myosin phosphatase. J. Biol. Chem. 1994, 269:30407-30411.
20. Surks H.K., Richards C.T., Mendelsohn M.E. Myosin phosphatase-Rho interacting protein. A new member of the myosin phosphatase complex that directly binds RhoA. J. Biol. Chem. 2003, 278:51484-51493.
21. Riddick N., Ohtani K., Surks H.K. Targeting by myosin phosphatase-RhoA interacting protein mediates RhoA/ROCK regulation of myosin phosphatase. J. Cell. Biochem. 2008, 103:1158-1170.
22. Wang Y., Zheng X.R., Riddick N., Bryden M., Baur W., Zhang X., Surks H.K. ROCK isoform regulation of myosin phosphatase and contractility in vascular smooth muscle cells. Circ. Res. 2009, 104:531-540.
23. Kawano Y., Fukata Y., Oshiro N., Amano M., Nakamura T., Ito M., Matsumura F., Inagaki M., Kaibuchi K. Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase by Rho-kinase in vivo. J. Cell Biol. 1999, 147:1023-1038.
24. Feng J., Ito M., Ichikawa K., Isaka N., Nishikawa M., Hartshorne D.J., Nakano T. Inhibitory phosphorylation site for Rho-associated kinase on smooth muscle myosin phosphatase. J. Biol. Chem. 1999, 274:37385-37390.
25. Shin H.M., Je H.D., Gallant C., Tao T.C., Hartshorne D.J., Ito M., Morgan K.G. Differential association and localization of myosin phosphatase subunits during agonist-induced signal transduction in smooth muscle. Circ. Res. 2002, 90:546-553.
26. Amano M., Ito M., Kimura K., Fukata Y., Chihara K., Nakano T., Matsuura Y., Kaibuchi K. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J. Biol. Chem. 1996, 271:20246-20249.
27. Iizuka K., Yoshii A., Samizo K., Tsukagoshi H., Ishizuka T., Dobashi K., Nakazawa T., Mori M. A major role for the rho-associated coiled coil forming protein kinase in G-protein-mediated Ca2+ sensitization through inhibition of myosin phosphatase in rabbit trachea. Br. J. Pharmacol. 1999, 128:925-933.
28. Sward K., Dreja K., Susnjar M., Hellstrand P., Hartshorne D.J., Walsh M.P. Inhibition of Rho-associated kinase blocks agonist-induced Ca2+ sensitization of myosin phosphorylation and force in guinea-pig ileum. J. Physiol. 2000, 522(Pt 1):33-49.
29. Kitazawa T., Eto M., Woodsome T.P., Brautigan D.L. Agonists trigger G protein-mediated activation of the CPI-17 inhibitor phosphoprotein of myosin light chain phosphatase to enhance vascular smooth muscle contractility. J. Biol. Chem. 2000, 275:9897-9900.
30. Eto M., Kitazawa T., Brautigan D.L. Phosphoprotein inhibitor CPI-17 specificity depends on allosteric regulation of protein phosphatase-1 by regulatory subunits. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:8888-8893.
31. Eto M., Kitazawa T., Matsuzawa F., Aikawa S., Kirkbride J.A., Isozumi N., Nishimura Y., Brautigan D.L., Ohki S.Y. Phosphorylation-induced conformational switching of CPI-17 produces a potent myosin phosphatase inhibitor. Structure 2007, 15:1591-1602.
32. Koyama M., Ito M., Feng J., Seko T., Shiraki K., Takase K., Hartshorne D.J., Nakano T. Phosphorylation of CPI-17, an inhibitory phosphoprotein of smooth muscle myosin phosphatase, by Rho-kinase. FEBS Lett. 2000, 475:197-200.
33. Riento K., Totty N., Villalonga P., Garg R., Guasch R., Ridley A.J. RhoE function is regulated by ROCK I-mediated phosphorylation. EMBO J. 2005, 24:1170-1180.
34. Noma K., Rikitake Y., Oyama N., Yan G., Alcaide P., Liu P.Y., Wang H., Ahl D., Sawada N., Okamoto R., Hiroi Y., Shimizu K., Luscinskas F.W., Sun J., Liao J.K. ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J. Clin. Invest. 2008, 118:1632-1644.
35. Rikitake Y., Oyama N., Wang C.Y., Noma K., Satoh M., Kim H.H., Liao J.K. Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/- haploinsufficient mice. Circulation 2005, 112:2959-2965.
36. Sah V.P., Minamisawa S., Tam S.P., Wu T.H., Dorn G.W., Ross J., Chien K.R., Brown J.H. Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. J. Clin. Invest. 1999, 103:1627-1634.
37. Patel C.A., Rattan S. Spontaneously tonic smooth muscle has characteristically higher levels of RhoA/ROK compared with the phasic smooth muscle. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 291:G830-G837.
38. Bolz S.S., Vogel L., Sollinger D., Derwand R., Boer C., Pitson S.M., Spiegel S., Pohl U. Sphingosine kinase modulates microvascular tone and myogenic responses through activation of RhoA/Rho kinase. Circulation 2003, 108:342-347.
39. Gokina N.I., Park K.M., McElroy-Yaggy K., Osol G. Effects of Rho kinase inhibition on cerebral artery myogenic tone and reactivity. J. Appl. Physiol. 2005, 98:1940-1948.
40. Ai S., Kuzuya M., Koike T., Asai T., Kanda S., Maeda K., Shibata T., Iguchi A. Rho-Rho kinase is involved in smooth muscle cell migration through myosin light chain phosphorylation-dependent and independent pathways. Atherosclerosis 2001, 155:321-327.
41. Li S., Moon J.J., Miao H., Jin G., Chen B.P., Yuan S., Hu Y., Usami S., Chien S. Signal transduction in matrix contraction and the migration of vascular smooth muscle cells in three-dimensional matrix. J. Vasc. Res. 2003, 40:378-388.
42. Chang Y., Ceacareanu B., Dixit M., Sreejayan N., Hassid A. Nitric oxide-induced motility in aortic smooth muscle cells: role of protein tyrosine phosphatase SHP-2 and GTP-binding protein Rho. Circ. Res. 2002, 91:390-397.
43. Kamiyama M., Utsunomiya K., Taniguchi K., Yokota T., Kurata H., Tajima N., Kondo K. Contribution of Rho A and Rho kinase to platelet-derived growth factor-BB-induced proliferation of vascular smooth muscle cells. J. Atheroscler. Thromb. 2003, 10:117-123.
44. Yamakawa T., Tanaka S., Numaguchi K., Yamakawa Y., Motley E.D., Ichihara S., Inagami T. Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension 2000, 35:313-318.
45. Negoro N., Hoshiga M., Seto M., Kohbayashi E., Ii M., Fukui R., Shibata N., Nakakoji T., Nishiguchi F., Sasaki Y., Ishihara T., Ohsawa N. The kinase inhibitor fasudil (HA-1077) reduces intimal hyperplasia through inhibiting migration and enhancing cell loss of vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 1999, 262:211-215.
46. Shibata R., Kai H., Seki Y., Kato S., Morimatsu M., Kaibuchi K., Imaizumi T. Role of Rho-associated kinase in neointima formation after vascular injury. Circulation 2001, 103:284-289.
47. Owens G.K., Kumar M.S., Wamhoff B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev. 2004, 84:767-801.
48. Liu H.W., Halayko A.J., Fernandes D.J., Harmon G.S., McCauley J.A., Kocieniewski P., McConville J., Fu Y., Forsythe S.M., Kogut P., Bellam S., Dowell M., Churchill J., Lesso H., Kassiri K., Mitchell R.W., Hershenson M.B., Camoretti-Mercado B., Solway J. The RhoA/Rho kinase pathway regulates nuclear localization of serum response factor. Am. J. Respir. Cell Mol. Biol. 2003, 29:39-47.
49. Mack C.P., Somlyo A.V., Hautmann M., Somlyo A.P., Owens G.K. Smooth muscle differentiation marker gene expression is regulated by RhoA-mediated actin polymerization. J. Biol. Chem. 2001, 276:341-347.
50. Uehata M., Ishizaki T., Satoh H., Ono T., Kawahara T., Morishita T., Tamakawa H., Yamagami K., Inui J., Maekawa M., Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997, 389:990-994.
51. Mukai Y., Shimokawa H., Matoba T., Kandabashi T., Satoh S., Hiroki J., Kaibuchi K., Takeshita A. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J. 2001, 15:1062-1064.
52. Asano M., Nomura Y. Comparison of inhibitory effects of Y-27632, a Rho kinase inhibitor, in strips of small and large mesenteric arteries from spontaneously hypertensive and normotensive Wistar-Kyoto rats. Hypertens. Res. 2003, 26:97-106.
53. Chrissobolis S., Sobey C.G. Evidence that Rho-kinase activity contributes to cerebral vascular tone in vivo and is enhanced during chronic hypertension: comparison with protein kinase C. Circ. Res. 2001, 88:774-779.
54. Weber D.S., Webb R.C. Enhanced relaxation to the rho-kinase inhibitor Y-27632 in mesenteric arteries from mineralocorticoid hypertensive rats. Pharmacology 2001, 63:129-133.
55. Seko T., Ito M., Kureishi Y., Okamoto R., Moriki N., Onishi K., Isaka N., Hartshorne D.J., Nakano T. Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ. Res. 2003, 92:411-418.
56. Seasholtz T.M., Zhang T., Morissette M.R., Howes A.L., Yang A.H., Brown J.H. Increased expression and activity of RhoA are associated with increased DNA synthesis and reduced p27(Kip1) expression in the vasculature of hypertensive rats. Circ. Res. 2001, 89:488-495.
57. Moriki N., Ito M., Seko T., Kureishi Y., Okamoto R., Nakakuki T., Kongo M., Isaka N., Kaibuchi K., Nakano T. RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Hypertens. Res. 2004, 27:263-270.
58. Wehrwein E.A., Northcott C.A., Loberg R.D., Watts S.W. Rho/Rho kinase and phosphoinositide 3-kinase are parallel pathways in the development of spontaneous arterial tone in deoxycorticosterone acetate-salt hypertension. J. Pharmacol. Exp. Ther. 2004, 309:1011-1019.
59. Ito K., Hirooka Y., Kishi T., Kimura Y., Kaibuchi K., Shimokawa H., Takeshita A. Rho/Rho-kinase pathway in the brainstem contributes to hypertension caused by chronic nitric oxide synthase inhibition. Hypertension 2004, 43:156-162.
60. Ito K., Hirooka Y., Sakai K., Kishi T., Kaibuchi K., Shimokawa H., Takeshita A. Rho/Rho-kinase pathway in brain stem contributes to blood pressure regulation via sympathetic nervous system: possible involvement in neural mechanisms of hypertension. Circ. Res. 2003, 92:1337-1343.
61. Chitaley K., Weber D., Webb R.C. RhoA/Rho-kinase, vascular changes, and hypertension. Curr. Hypertens. Rep. 2001, 3:139-144.
62. Kataoka C., Egashira K., Inoue S., Takemoto M., Ni W., Koyanagi M., Kitamoto S., Usui M., Kaibuchi K., Shimokawa H., Takeshita A. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 2002, 39:245-250.
63. Ying Z., Jin L., Dorrance A.M., Webb R.C. Increaseed expression of mRNA for regulator of G protein signaling domain-containing Rho guanine nucleotide exchange factors in aorta from stroke-prone spontaneously hypertensive rats. Am. J. Hypertens. 2004, 17:981-985.
64. Wirth A., Benyo Z., Lukasova M., Leutgeb B., Wettschureck N., Gorbey S., Orsy P., Horvath B., Maser-Gluth C., Greiner E., Lemmer B., Schutz G., Gutkind J.S., Offermanns S. G12-G13-LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension. Nat. Med. 2008, 14:64-68.
65. Lassegue B., Griendling K.K. Reactive oxygen species in hypertension; An update. Am. J. Hypertens. 2004, 17:852-860.
66. Touyz R.M., Schiffrin E.L. Reactive oxygen species in vascular biology: implications in hypertension. Histochem. Cell Biol. 2004, 122:339-352.
67. Jin L., Ying Z., Webb R.C. Activation of Rho/Rho kinase signaling pathway by reactive oxygen species in rat aorta. Am. J. Physiol. Heart Circ. Physiol. 2004, 287:H1495-H1500.
68. Ibald-Mulli A., Stieber J., Wichmann H.E., Koenig W., Peters A. Effects of air pollution on blood pressure: a population-based approach. Am. J. Public Health 2001, 91:571-577.
69. Sun Q., Yue P., Ying Z., Cardounel A.J., Brook R.D., Devlin R., Hwang J.S., Zweier J.L., Chen L.C., Rajagopalan S. Air pollution exposure potentiates hypertension through reactive oxygen species-mediated activation of Rho/ROCK. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1760-1766.
70. Shao J., Welch W.J., Diprospero N.A., Diamond M.I. Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation. Mol. Cell. Biol. 2008, 28:5196-5208.
71. Moustafa-Bayoumi M., Alhaj M.A., El-Sayed O., Wisel S., Chotani M.A., Abouelnaga Z.A., Hassona M.D., Rigatto K., Morris M., Nuovo G., Zweier J.L., Goldschmidt-Clermont P., Hassanain H. Vascular hypertrophy and hypertension caused by transgenic overexpression of profilin 1. J. Biol. Chem. 2007, 282:37632-37639.
72. Higashi M., Shimokawa H., Hattori T., Hiroki J., Mukai Y., Morikawa K., Ichiki T., Takahashi S., Takeshita A. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ. Res. 2003, 93:767-775.
73. Masumoto A., Hirooka Y., Shimokawa H., Hironaga K., Setoguchi S., Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 2001, 38:1307-1310.
74. Kishi T., Hirooka Y., Masumoto A., Ito K., Kimura Y., Inokuchi K., Tagawa T., Shimokawa H., Takeshita A., Sunagawa K. Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure. Circulation 2005, 111:2741-2747.
75. Noma K., Higashi Y., Jitsuiki D., Hara K., Kimura M., Nakagawa K., Goto C., Oshima T., Yoshizumi M., Chayama K. Smoking activates rho-kinase in smooth muscle cells of forearm vasculature in humans. Hypertension 2003, 41:1102-1105.
76. Seasholtz T.M., Wessel J., Rao F., Rana B.K., Khandrika S., Kennedy B.P., Lillie E.O., Ziegler M.G., Smith D.W., Schork N.J., Brown J.H., O'Connor D.T. Rho kinase polymorphism influences blood pressure and systemic vascular resistance in human twins: role of heredity. Hypertension 2006, 47:937-947.
77. Rankinen T., Church T., Rice T., Markward N., Blair S.N., Bouchard C. A major haplotype block at the rho-associated kinase 2 locus is associated with a lower risk of hypertension in a recessive manner: the HYPGENE study. Hypertens. Res. 2008, 31:1651-1657.
78. Lucas K.A., Pitari G.M., Kazerounian S., Ruiz-Stewart I., Park J., Schulz S., Chepenik K.P., Waldman S.A. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol. Rev. 2000, 52:375-414.
79. Schlossmann J., Feil R., Hofmann F. Signaling through NO and cGMP-dependent protein kinases. Ann. Med. 2003, 35:21-27.
80. Surks H.K., Mochizuki N., Kasai Y., Georgescu S.P., Tang K.M., Ito M., Lincoln T.M., Mendelsohn M.E. Regulation of myosin phosphatase by a specific interaction with cGMP- dependent protein kinase Ialpha. Science 1999, 286:1583-1587.
81. Chou T.C., Yen M.H., Li C.Y., Ding Y.A. Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension 1998, 31:643-648.
82. Huang P.L., Huang Z., Mashimo H., Bloch K.D., Moskowitz M.A., Bevan J.A., Fishman M.C. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995, 377:239-242.
83. Sauzeau V., Le Jeune H., Cario-Toumaniantz C., Smolenski A., Lohmann S.M., Bertoglio J., Chardin P., Pacaud P., Loirand G. Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle. J. Biol. Chem. 2000, 275:21722-21729.
84. Chitaley K., Webb R.C. Nitric oxide induces dilation of rat aorta via inhibition of rho-kinase signaling. Hypertension 2002, 39:438-442.
85. Carter R.W., Begaye M., Kanagy N.L. Acute and chronic NOS inhibition enhances alpha(2)- adrenoreceptor-stimulated RhoA and Rho kinase in rat aorta. Am. J. Physiol. Heart Circ. Physiol. 2002, 283:H1361-H1369.
86. Laufs U., Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 1998, 273:24266-24271.
87. Chen H., Ikeda U., Shimpo M., Ikeda M., Minota S., Shimada K. Fluvastatin upregulates inducible nitric oxide synthase expression in cytokine-stimulated vascular smooth muscle cells. Hypertension 2000, 36:923-928.
88. Shiga N., Hirano K., Hirano M., Nishimura J., Nawata H., Kanaide H. Long-term inhibition of RhoA attenuates vascular contractility by enhancing endothelial NO production in an intact rabbit mesenteric artery. Circ. Res. 2005, 96:1014-1021.
89. Wolfrum S., Dendorfer A., Rikitake Y., Stalker T.J., Gong Y., Scalia R., Dominiak P., Liao J.K. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler. Thromb. Vasc. Biol. 2004, 24:1842-1847.
90. Eto M., Barandier C., Rathgeb L., Kozai T., Joch H., Yang Z., Luscher T.F. Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ. Res. 2001, 89:583-590.
91. Takemoto M., Sun J., Hiroki J., Shimokawa H., Liao J.K. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002, 106:57-62.
92. Rikitake Y., Kim H.H., Huang Z., Seto M., Yano K., Asano T., Moskowitz M.A., Liao J.K. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005, 36:2251-2257.
93. Ishizaki T., Uehata M., Tamechika I., Keel J., Nonomura K., Maekawa M., Narumiya S. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol. Pharmacol. 2000, 57:976-983.
94. Davies S.P., Reddy H., Caivano M., Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000, 351:95-105.
95. Nagumo H., Sasaki Y., Ono Y., Okamoto H., Seto M., Takuwa Y. Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells. Am. J. Physiol. Cell Physiol. 2000, 278:C57-C65.
96. Shimokawa H., Seto M., Katsumata N., Amano M., Kozai T., Yamawaki T., Kuwata K., Kandabashi T., Egashira K., Ikegaki I., Asano T., Kaibuchi K., Takeshita A. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc. Res. 1999, 43:1029-1039.
97. Tachibana E., Harada T., Shibuya M., Saito K., Takayasu M., Suzuki Y., Yoshida J. Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage. Acta Neurochir. (Wien) 1999, 141:13-19.
98. Shimokawa H., Hiramori K., Iinuma H., Hosoda S., Kishida H., Osada H., Katagiri T., Yamauchi K., Yui Y., Minamino T., Nakashima M., Kato K. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J. Cardiovasc. Pharmacol. 2002, 40:751-761.
99. Vicari R.M., Chaitman B., Keefe D., Smith W.B., Chrysant S.G., Tonkon M.J., Bittar N., Weiss R.J., Morales-Ballejo H., Thadani U. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J. Am. Coll. Cardiol. 2005, 46:1803-1811.
100. Inokuchi K., Ito A., Fukumoto Y., Matoba T., Shiose A., Nishida T., Masuda M., Morita S., Shimokawa H. Usefulness of fasudil, a Rho-kinase inhibitor, to treat intractable severe coronary spasm after coronary artery bypass surgery. J. Cardiovasc. Pharmacol. 2004, 44:275-277.
101. Mohri M., Shimokawa H., Hirakawa Y., Masumoto A., Takeshita A. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J. Am. Coll. Cardiol. 2003, 41:15-19.
102. Shibuya M., Hirai S., Seto M., Satoh S., Ohtomo E. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J. Neurol. Sci. 2005, 238:31-39.
103. Fukumoto Y., Matoba T., Ito A., Tanaka H., Kishi T., Hayashidani S., Abe K., Takeshita A., Shimokawa H. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005, 91:391-392.
104. Chen X.Y., Dun J.N., Miao Q.F., Zhang Y.J. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses 5-hydroxytryptamine-induced pulmonary artery smooth muscle cell proliferation via JNK and ERK1/2 pathway. Pharmacology 2009, 83:67-79.
105. Doe C., Bentley R., Behm D.J., Lafferty R., Stavenger R., Jung D., Bamford M., Panchal T., Grygielko E., Wright L.L., Smith G.K., Chen Z., Webb C., Khandekar S., Yi T., Kirkpatrick R., Dul E., Jolivette L., Marino J.P., Willette R., Lee D., Hu E. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J. Pharmacol. Exp. Ther. 2007, 320:89-98.
106. Nakajima M., Katayama K., Tamechika I., Hayashi K., Amano Y., Uehata M., Goto N., Kondo T. WF-536 inhibits metastatic invasion by enhancing the host cell barrier and inhibiting tumour cell motility. Clin. Exp. Pharmacol. Physiol. 2003, 30:457-463.
107. Nakajima E., Nakajima T., Minagawa Y., Shearer T.R., Azuma M. Contribution of ROCK in contraction of trabecular meshwork: proposed mechanism for regulating aqueous outflow in monkey and human eyes. J. Pharm. Sci. 2005, 94:701-708.
108. Tamura M., Nakao H., Yoshizaki H., Shiratsuchi M., Shigyo H., Yamada H., Ozawa T., Totsuka J., Hidaka H. Development of specific Rho-kinase inhibitors and their clinical application. Biochim. Biophys. Acta 2005, 1754:245-252.
109. Boerma M., Fu Q., Wang J., Loose D.S., Bartolozzi A., Ellis J.L., McGonigle S., Paradise E., Sweetnam P., Fink L.M., Vozenin-Brotons M.C., Hauer-Jensen M. Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin. Blood Coagul. Fibrinolysis 2008, 19:709-718.
110. Schueller O., Tong W., Ferkany J.W., Sweetnam P. Abstract 1216: Selective ROCK 2 inhibition attenuates arterial plaque formation in an ApoE knockout mouse model. Circulation 2006, 114(II):228.
111. Liao J.K., Laufs U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 2005, 45:89-118.
112. Landmesser U., Bahlmann F., Mueller M., Spiekermann S., Kirchhoff N., Schulz S., Manes C., Fischer D., de Groot K., Fliser D., Fauler G., Marz W., Drexler H. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005, 111:2356-2363.
113. Marketou M.E., Zacharis E.A., Nikitovic D., Ganotakis E.S., Parthenakis F.I., Maliaraki N., Vardas P.E. Early effects of simvastatin versus atorvastatin on oxidative stress and proinflammatory cytokines in hyperlipidemic subjects. Angiology 2006, 57:211-218.
114. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998, 279:509-514.
115. Liu P.Y., Liu Y.W., Lin L.J., Chen J.H., Liao J.K. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 2009, 119:131-138.
116. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D.J., Sessa W.C., Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 2000, 6:1004-1010.
117. Endres M., Laufs U., Huang Z., Nakamura T., Huang P., Moskowitz M.A., Liao J.K. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:8880-8885.
118. Kaneko T., Amano M., Maeda A., Goto H., Takahashi K., Ito M., Kaibuchi K. Identification of calponin as a novel substrate of Rho-kinase. Biochem. Biophys. Res. Commun. 2000, 273:110-116.
119. Fukata Y., Oshiro N., Kinoshita N., Kawano Y., Matsuoka Y., Bennett V., Matsuura Y., Kaibuchi K. Phosphorylation of adducin by Rho-kinase plays a crucial role in cell motility. J. Cell Biol. 1999, 145:347-361.
120. Ohashi K., Nagata K., Maekawa M., Ishizaki T., Narumiya S., Mizuno K. Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. J. Biol. Chem. 2000, 275:3577-3582.
121. Sumi T., Matsumoto K., Nakamura T. Specific activation of LIM kinase 2 via phosphorylation of threonine 505 by ROCK, a Rho-dependent protein kinase. J. Biol. Chem. 2001, 276:670-676.
122. Hagerty L., Weitzel D.H., Chambers J., Fortner C.N., Brush M.H., Loiselle D., Hosoya H., Haystead T.A. ROCK1 phosphorylates and activates zipper-interacting protein kinase. J. Biol. Chem. 2007, 282:4884-4893.
123. Goto H., Kosako H., Tanabe K., Yanagida M., Sakurai M., Amano M., Kaibuchi K., Inagaki M. Phosphorylation of vimentin by Rho-associated kinase at a unique amino-terminal site that is specifically phosphorylated during cytokinesis. J. Biol. Chem. 1998, 273:11728-11736.
124. Li Z., Dong X., Wang Z., Liu W., Deng N., Ding Y., Tang L., Hla T., Zeng R., Li L., Wu D. Regulation of PTEN by Rho small GTPases. Nat. Cell Biol. 2005, 7:399-404.